medigraphic.com
Academia Mexicana de Neurología, A.C.

2014, Number 2

<< Back Next >>

Rev Mex Neuroci 2014; 15 (2)

Clinical experience with intravenous levetiracetam in 48 pediatric patients for the management of acute seizures and uncontrolled epilepsy

Peña-Landín DM, Ruíz GM

Language: Spanish
References: 30
Page: 87-92
PDF size: 144.23 Kb.


ABSTRACT

Introduction: In the treatment of epilepsy it is necessary to select drugs with high efficacy and minimum side effects. Levetiracetam seems to have an ideal pharmacological profile. Although the oral route is the usual form of administration, sometimes it is required the intravenous administration.
Objective: To describe the clinical profile, indications in intravenous administration and seizures control of 48 pediatric epileptic patients managed with intravenous levetiracetam in monotherapy or add-on therapy.
Methods: This is a retrospective and observational study performed at the National Institute of Pediatrics between February 2011 to April 2013, in patients receiving intravenous levetiracetam, for whom the enteral route was contraindicated.
Results: A total of 48 records were included, 60% of the population ‹ 2 years. Symptomatic focal epilepsy was present in 39 patients (81%). The most common etiologies were: hypoxic-ischemic encephalopathy (HIE) (n = 14), cerebral dysgenesis (n = 10) and acquired metabolic disorders (n = 7). Indications for intravenous administration: uncontrolled seizures (n = 23) and fasting due to medical illness (n = 11). A total of 43 patients (89.5%) were seizure-free during the first 24 h. Intravenous administration was performed with dose 20 mg/kg b.i.d. and the patients received 2 to 6 IV doses, without any adverse effects. Once the enteral route was restored, the change from intravenous to oral route was made in equivalent doses. In all, 35 patients (73%) maintained levetiracetam treatment in mono/politherapy for up to 36 months (average 18.5 months, SD ± 10.5). A total of 13 patients (27%) discontinued levetiracetam, none for therapeutic failure, 1 patient developed aggression during the first week as adverse event and suspended levetiracetam, followed by economic hardship.
Conclusions: This series shows that levetiracetam is an antiepileptic drug that enabled adequate control in acute seizures and chronic management of epilepsy. Adherence was obtained in 80% of patients. The levetiracetam is a safe, broad-spectrum antiepileptic with few adverse effects and is a good option for intravenous use in children.


REFERENCES

  1. Cormier J, Chu C. Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age. Neuropsychiatric Disease and Treatment 2013; 9: 295-306.

  2. Shinnar S, Pellock JM. Update on the epidemiology and prognosis of pediatric epilepsy. J Child Neurol 2002; 17 Suppl 1:S4-S17.

  3. Jiahui L, Xiao N, Chen S. Efficacy and tolerability of Levetiracetam in children with epilepsy. Brain & Development 2011; 33: 145-51.

  4. Giner JC, Hernández RL, Sempere A, Bosacoma Ros L, Berenguer L, et al. Utilización de levetiracetam intravenoso en un hospital general. Rev Neurol 2009; 49: 517-19.

  5. Santos J, Benítez A, Castro E. Levetiracetam endovenoso en el tratamiento de la epilepsia en la sala de urgencias. Arch Med Urg Mex 2011; 3: 33-40.

  6. Aceves J, Khan O, Mungall D, et al. Efficacy and tolerability of intravenous levetiracetam in children. Frontiers in Neurology 2013; 4: 1-5.

  7. Panayiotopoulos CP. Epilepsies vade mecum: epileptic seizures, epileptic syndromes, antiepileptic drug therapy. Oxford: 2010.

  8. Stephen LJ, Kelly K, Parker P, Brodie MJ. Levetiracetam monotherapy— outcomes from an epilepsy clinic. Seizure 2011; 20: 554-7.

  9. Khurana DS, Kothare SV, Valencia I, Melvin JJ, Legido A. Levetiracetam monotherapy in children with epilepsy. Pediatr Neurol 2007; 36: 227-30.

  10. Perry S, Holt P, Benatar M. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. J Child Neurol 2008; 23: 515-19.

  11. Lynch B, Lambeng N, Nocka K, Kensel-Hammes P, Baijalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci 2004; 101: 9861-6.

  12. Yang F, Weisenfeld A, Rothman S. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007; 48: 1861-9.

  13. Dedeurwaerdere S, et al. Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepy. Acta Neurol Belg 2006; 106: 91-7.

  14. Ruiz M, Munive L. tratamiento farmacológico. Levetiracetam en el paciente pediátrico. Cap. 6. Epilepsia, un enfoque actual. Sentíes H. Ed. Alfil; 2012, p. 45-58.

  15. Giner BJC, Hernández RL, Sempere A. Bosacoma Ros L, Berenguer L, et al. Utilización de levetiracetam intravenoso en un hospital general. Rev Neurol 2009; 49: 517-19.

  16. Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. Epilepsy Res 2007; 76: 140-7.

  17. Bert AT, et al. Revised terminology and Concepts for organization of seizures and epilepsias: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-85.

  18. Rüegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008; 12: 477-80.

  19. Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, et al. Intravenous levetiracetam in the treatment of benzodiazepinerefractory status epilepticus. J Neurol Neurosurg Psychiatry 2008; 79: 588-9.

  20. Ahmed A, Rawabi K, Rawan H. Efficacy and safety of levetiracetam in pediatric epilepsy. Saudi Pharmaceutical Journal 2012; 20: 81-4.

  21. Merhar S, Schibler K, Sherwin C, et al. Pharmacokinetics of Levetiracetam in neonatos with seizures. J Pediatr 2011; 159: 152-4.

  22. Abend N, Monk H, Licht D, Dlugos D. Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures. Pediatr Crit Care Med 2009; 10: 505-10.

  23. Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Openlabel, noncomparative, multicenter, long-term follow-up study. Epilepsia 2012; 53: 111-19.

  24. Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 2005; 14: 66-71.

  25. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.

  26. Weinstock A, Ruiz M, Gerard D, Toubland N, Stockis A, Farooq O, Dilley D, et al. Prospective Open-Label, Single-Arm, Multicenter, Safety, Tolerability, and Pharmacokinetic Studies of Intravenous Levetiracetam in Children With Epilepsy. J Child Neurol 2013; 00: 1- 7.

  27. Perry MS, Benatar M. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Epilepsia 2007; 48: 1123-7.

  28. Grosso S, Cordelli DM, Franzoni E, Coppola G, Capovilla G, Zamponi N, et al. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure 2007; 16: 345-50.

  29. Varelas PN, Spanaki M. Management of seizures in the critically ill. Neurologist 2006; 12: 127-39.

  30. Ríos FB, Ibarra PJ, Olivas PE, Munive BL. Levetiracetam en crisis convulsivas refractarias de inicio en la etapa neonatal: experiencia en el Instituto Nacional de Perinatología. Rev Mex Neuroci 2010; 11: 199-204.




2020     |     www.medigraphic.com